Crescent Biopharma(CBIO)
Focus: Crescent Biopharma is a publicly traded oncology-focused pharmaceutical company headquartered in Waltham, MA, founded in 2016 with a clinical-stage pipeline centered on solid tumors and specialized indications. The company operates with minimal commercial revenue and is pre-profitability.
Profile data last refreshed 41m ago · AI intelligence enriched 2w ago
Funding Stage
PUBLIC
Open Jobs
14+11 this month
Growing — net +11 jobs in 30d
12 jobs added vs 1 removed. Steady team buildout.
Should You Work at Crescent Biopharma?
AI assessmentHigh-risk early-stage opportunity suitable only for researchers/scientists willing to bet on a cash-constrained oncology play with uncertain runway and no near-term value inflection.
Why Work Here
- Public company status (NASDAQ: CBIO) provides liquidity, equity value transparency, and established governance structures versus private biotech.
Data completeness
5/9 — Partial
Company HealthStrong
Pipeline
Early-stage
9 total
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Revenue
$0K
Pipeline & Clinical Trials
Folic acid
Acute Myocardial InfarctionClinical Trials (1)
NCT00266487The Norwegian Vitamin Trial (NORVIT)
N/AHelp build intelligence for Crescent Biopharma
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.